

# James R Eshleman

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6833425/publications.pdf>

Version: 2024-02-01

121  
papers

34,560  
citations

53939

47  
h-index

21843

118  
g-index

123  
all docs

123  
docs citations

123  
times ranked

40921  
citing authors

#	ARTICLE	IF	CITATIONS
1	Validation of Long Mononucleotide Repeat Markers for Detection of Microsatellite Instability. <i>Journal of Molecular Diagnostics</i> , 2022, 24, 144-157.	1.2	10
2	Functional CDKN2A assay identifies frequent deleterious alleles misclassified as variants of uncertain significance. <i>ELife</i> , 2022, 11, .	2.8	6
3	Utility of targeted next-generation sequencing assay to detect 1p/19q co-deletion in formalin-fixed paraffin-embedded glioma specimens. <i>Human Pathology</i> , 2022, 126, 63-76.	1.1	5
4	PIN-like ductal carcinoma of the prostate has frequent activating RAS/RAF mutations. <i>Histopathology</i> , 2021, 78, 327-333.	1.6	9
5	Tumor Frameshift Mutation Proportion Predicts Response to Immunotherapy in Mismatch Repair-Deficient Prostate Cancer. <i>Oncologist</i> , 2021, 26, e270-e278.	1.9	33
6	Nivolumab plus ipilimumab, with or without enzalutamide, in AR-V7-expressing metastatic castration-resistant prostate cancer: A phase 2 nonrandomized clinical trial. <i>Prostate</i> , 2021, 81, 326-338.	1.2	35
7	Val16A SOD2 Polymorphism Promotes Epithelial-Mesenchymal Transition Antagonized by Muscadine Grape Skin Extract in Prostate Cancer Cells. <i>Antioxidants</i> , 2021, 10, 213.	2.2	2
8	Pancreatic cancer pathology viewed in the light of evolution. <i>Cancer and Metastasis Reviews</i> , 2021, 40, 661-674.	2.7	7
9	Heat Shock Protein 90 Inhibitor Effects on Pancreatic Cancer Cell Cultures. <i>Pancreas</i> , 2021, 50, 625-632.	0.5	2
10	IDH1 and IDH2 Mutations in Colorectal Cancers. <i>American Journal of Clinical Pathology</i> , 2021, 156, 777-786.	0.4	12
11	Double PIK3CA Alterations and Parallel Evolution in Colorectal Cancers. <i>American Journal of Clinical Pathology</i> , 2021, , .	0.4	0
12	CloneRetriever: An Automated Algorithm to Identify Clonal B and T Cell Gene Rearrangements by Next-Generation Sequencing for the Diagnosis of Lymphoid Malignancies. <i>Clinical Chemistry</i> , 2021, 67, 1524-1533.	1.5	1
13	A Cost-Effective and Non-Invasive pfeRNA-Based Test Differentiates Benign and Suspicious Pulmonary Nodules from Malignant Ones. <i>Non-coding RNA</i> , 2021, 7, 80.	1.3	2
14	Gene Variants That Affect Levels of Circulating Tumor Markers Increase Identification of Patients With Pancreatic Cancer. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 1161-1169.e5.	2.4	31
15	Comprehensive mutagenesis on yeast cytosine deaminase yields improvements in 5-fluorocytosine toxicity in HT1080 cells. <i>AICHE Journal</i> , 2020, 66, e16688.	1.8	3
16	Tetraploid Partial Hydatidiform Moles. <i>Journal of Molecular Diagnostics</i> , 2020, 22, 90-100.	1.2	12
17	Successful gene therapy requires targeting the vast majority of cancer cells. <i>Cancer Biology and Therapy</i> , 2020, 21, 946-953.	1.5	1
18	Molecular characterization of organoids derived from pancreatic intraductal papillary mucinous neoplasms. <i>Journal of Pathology</i> , 2020, 252, 252-262.	2.1	30

#	ARTICLE	IF	CITATIONS
19	The genetics of ductal adenocarcinoma of the pancreas in the year 2020: dramatic progress, but far to go. <i>Modern Pathology</i> , 2020, 33, 2544-2563.	2.9	23
20	Patient-derived Organoid Pharmacotyping is a Clinically Tractable Strategy for Precision Medicine in Pancreatic Cancer. <i>Annals of Surgery</i> , 2020, 272, 427-435.	2.1	61
21	Clonal Origin Evaluated by Trunk and Branching Drivers and Prevalence of Mutations in Multiple Lung Tumor Nodules. <i>Molecular Diagnosis and Therapy</i> , 2020, 24, 461-472.	1.6	3
22	<i>HIST1H2BB</i> and <i>MAGI2</i> Methylation and Somatic Mutations as Precision Medicine Biomarkers for Diagnosis and Prognosis of High-grade Serous Ovarian Cancer. <i>Cancer Prevention Research</i> , 2020, 13, 783-794.	0.7	11
23	Detection of Circulating Tumor DNA in Patients with Pancreatic Cancer Using Digital Next-Generation Sequencing. <i>Journal of Molecular Diagnostics</i> , 2020, 22, 748-756.	1.2	11
24	<i>IDH1</i> and <i>IDH2</i> mutations in lung adenocarcinomas: Evidences of subclonal evolution. <i>Cancer Medicine</i> , 2020, 9, 4386-4394.	1.3	18
25	Multiclonal colorectal cancers with divergent histomorphological features and RAS mutations: one cancer or separate cancers?. <i>Human Pathology</i> , 2020, 98, 120-128.	1.1	4
26	Clinical mutational profiling and categorization of BRAF mutations in melanomas using next generation sequencing. <i>BMC Cancer</i> , 2019, 19, 665.	1.1	42
27	A pilot study of prostate-specific membrane antigen (PSMA) dynamics in men undergoing treatment for advanced prostate cancer. <i>Prostate</i> , 2019, 79, 1597-1603.	1.2	18
28	Axon Guidance Molecules Promote Perineural Invasion and Metastasis of Orthotopic Pancreatic Tumors in Mice. <i>Gastroenterology</i> , 2019, 157, 838-850.e6.	0.6	88
29	Clinical Validation of Discordant Trunk Driver Mutations in Paired Primary and Metastatic Lung Cancer Specimens. <i>American Journal of Clinical Pathology</i> , 2019, 152, 570-581.	0.4	6
30	Circulating Tumor DNA as a Clinical Test in Resected Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 4973-4984.	3.2	118
31	A New Fast Phasing Method Based On Haplotype Subtraction. <i>Journal of Molecular Diagnostics</i> , 2019, 21, 427-436.	1.2	1
32	<i>JAK3</i> Variant, Immune Signatures, DNA Methylation, and Social Determinants Linked to Survival Racial Disparities in Head and Neck Cancer Patients. <i>Cancer Prevention Research</i> , 2019, 12, 255-270.	0.7	19
33	Prediction of Recurrence With KRAS Mutational Burden Using Ultrasensitive Digital Polymerase Chain Reaction of Radial Resection Margin of Resected Pancreatic Ductal Adenocarcinoma. <i>Pancreas</i> , 2019, 48, 400-411.	0.5	2
34	Biphenotypic Differentiation of Pancreatic Cancer in 3-Dimensional Culture. <i>Pancreas</i> , 2019, 48, 1225-1231.	0.5	2
35	Clinical Validation of Coexisting Activating Mutations Within EGFR, Mitogen-Activated Protein Kinase, and Phosphatidylinositol 3-Kinase Pathways in Lung Cancers. <i>Archives of Pathology and Laboratory Medicine</i> , 2019, 143, 174-182.	1.2	15
36	Clinical validation of coexisting driver mutations in colorectal cancers. <i>Human Pathology</i> , 2019, 86, 12-20.	1.1	10

#	ARTICLE	IF	CITATIONS
37	Mutations in the pancreatic secretory enzymes <i>CPA1</i> and <i>CPB1</i> are associated with pancreatic cancer. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 4767-4772.	3.3	65
38	Simple Detection of Telomere Fusions in Pancreatic Cancer, Intraductal Papillary Mucinous Neoplasm, and Pancreatic Cyst Fluid. Journal of Molecular Diagnostics, 2018, 20, 46-55.	1.2	16
39	Ipilimumab plus nivolumab and DNA-repair defects in AR-V7-expressing metastatic prostate cancer. Oncotarget, 2018, 9, 28561-28571.	0.8	129
40	Endocrine mucin-producing sweat gland carcinoma: A study of 11 cases with molecular analysis. Journal of Cutaneous Pathology, 2018, 45, 681-687.	0.7	28
41	Validation Strategy for Ultrasensitive Mutation Detection. Molecular Diagnosis and Therapy, 2018, 22, 603-611.	1.6	0
42	Alterations of type II classical cadherin, cadherin-10 (CDH10), is associated with pancreatic ductal adenocarcinomas. Genes Chromosomes and Cancer, 2017, 56, 427-435.	1.5	8
43	Patients with McCune-Albright syndrome have a broad spectrum of abnormalities in the gastrointestinal tract and pancreas. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2017, 470, 391-400.	1.4	39
44	Haplotype Counting for Sensitive Chimerism Testing. Journal of Molecular Diagnostics, 2017, 19, 427-436.	1.2	10
45	Susceptibility of ATM-deficient pancreatic cancer cells to radiation. Cell Cycle, 2017, 16, 991-998.	1.3	24
46	Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science, 2017, 357, 409-413.	6.0	4,945
47	Analytical Validation of Androgen Receptor Splice Variant 7 Detection in a Clinical Laboratory Improvement Amendments (CLIA) Laboratory Setting. Journal of Molecular Diagnostics, 2017, 19, 115-125.	1.2	41
48	MSH2 Loss in Primary Prostate Cancer. Clinical Cancer Research, 2017, 23, 6863-6874.	3.2	122
49	Morphology and genetics of pyloric gland adenomas in familial adenomatous polyposis. Histopathology, 2017, 70, 549-557.	1.6	20
50	Hypermutation In Pancreatic Cancer. Gastroenterology, 2017, 152, 68-74.e2.	0.6	174
51	Clinical Utility of CLIA-Grade AR-V7 Testing in Patients With Metastatic Castration-Resistant Prostate Cancer. JCO Precision Oncology, 2017, 2017, 1-9.	1.5	42
52	Phase 2 biomarker-driven study of ipilimumab plus nivolumab (Ipi/Nivo) for ARV7-positive metastatic castrate-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2017, 35, 5035-5035.	0.8	19
53	Clinical utility of CLIA-grade AR-V7 testing in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2017, 35, 183-183.	0.8	1
54	Clinical mutational profiling of 1006 lung cancers by next generation sequencing. Oncotarget, 2017, 8, 96684-96696.	0.8	32

#	ARTICLE	IF	CITATIONS
55	Heterogeneity of resistance mutations detectable by next-generation sequencing in TKI-treated lung adenocarcinoma. <i>Oncotarget</i> , 2016, 7, 45237-45248.	0.8	25
56	Molecular Diagnostics for Precision Medicine in Colorectal Cancer: Current Status and Future Perspective. <i>BioMed Research International</i> , 2016, 2016, 1-12.	0.9	19
57	Clinical mutational profiling of bone metastases of lung and colon carcinoma and malignant melanoma using next-generation sequencing. <i>Cancer Cytopathology</i> , 2016, 124, 744-753.	1.4	31
58	Cost-Savings Analysis of AR-V7 Testing in Patients With Metastatic Castration-Resistant Prostate Cancer Eligible for Treatment With Abiraterone or Enzalutamide. <i>Prostate</i> , 2016, 76, 1484-1490.	1.2	29
59	Test Feasibility of Next-Generation Sequencing Assays in Clinical Mutation Detection of Small Biopsy and Fine Needle Aspiration Specimens. <i>American Journal of Clinical Pathology</i> , 2016, 145, 696-702.	0.4	22
60	Nanopore sequencing detects structural variants in cancer. <i>Cancer Biology and Therapy</i> , 2016, 17, 246-253.	1.5	130
61	Whole Genome Sequencing Defines the Genetic Heterogeneity of Familial Pancreatic Cancer. <i>Cancer Discovery</i> , 2016, 6, 166-175.	7.7	282
62	Microsatellite Instability as a Biomarker for PD-1 Blockade. <i>Clinical Cancer Research</i> , 2016, 22, 813-820.	3.2	698
63	Association of <i>BRAF</i> <sup>V600E</sup> Mutation and MicroRNA Expression with Central Lymph Node Metastases in Papillary Thyroid Cancer: A Prospective Study from Four Endocrine Surgery Centers. <i>Thyroid</i> , 2016, 26, 532-542.	2.4	50
64	Genomic analyses identify molecular subtypes of pancreatic cancer. <i>Nature</i> , 2016, 531, 47-52.	13.7	2,700
65	Donor cell leukemia arising from clonal hematopoiesis after bone marrow transplantation. <i>Leukemia</i> , 2016, 30, 1916-1920.	3.3	79
66	Programmed death-1 blockade in mismatch repair deficient colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, 103-103.	0.8	50
67	PD-1 blockade in mismatch repair deficient non-colorectal gastrointestinal cancers.. <i>Journal of Clinical Oncology</i> , 2016, 34, 195-195.	0.8	39
68	Cost-benefit analysis of AR-V7 testing in patients (Pts) with metastatic castration resistant prostate cancer (mCRPC) eligible for abiraterone (Abi) or enzalutamide (Enza).. <i>Journal of Clinical Oncology</i> , 2016, 34, 283-283.	0.8	0
69	Transflap mutations produce deletions in pancreatic cancer. <i>Genes Chromosomes and Cancer</i> , 2015, 54, 472-481.	1.5	9
70	Clinical detection and categorization of uncommon and concomitant mutations involving BRAF. <i>BMC Cancer</i> , 2015, 15, 779.	1.1	92
71	PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. <i>New England Journal of Medicine</i> , 2015, 372, 2509-2520.	13.9	7,696
72	Familial and sporadic pancreatic cancer share the same molecular pathogenesis. <i>Familial Cancer</i> , 2015, 14, 95-103.	0.9	54

#	ARTICLE	IF	CITATIONS
73	Whole genomes redefine the mutational landscape of pancreatic cancer. <i>Nature</i> , 2015, 518, 495-501.	13.7	2,132
74	Performance characteristics of next-generation sequencing in clinical mutation detection of colorectal cancers. <i>Modern Pathology</i> , 2015, 28, 1390-1399.	2.9	53
75	Clinical implications of genomic alterations in the tumour and circulation of pancreatic cancer patients. <i>Nature Communications</i> , 2015, 6, 7686.	5.8	393
76	KRAS and Guanine Nucleotide-Binding Protein Mutations in Pancreatic Juice Collected From the Duodenum of Patients at High Risk for Neoplasia Undergoing Endoscopic Ultrasound. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 963-969.e4.	2.4	74
77	Non-p.V600E BRAF Mutations Are Common Using a More Sensitive and Broad Detection Tool. <i>American Journal of Clinical Pathology</i> , 2015, 144, 620-628.	0.4	43
78	Lymph node metastases of melanoma: challenges for BRAF mutation detection. <i>Human Pathology</i> , 2015, 46, 113-119.	1.1	16
79	PD-1 blockade in tumors with mismatch repair deficiency.. <i>Journal of Clinical Oncology</i> , 2015, 33, LBA100-LBA100.	0.8	22
80	PD-1 blockade in tumors with mismatch repair deficiency.. <i>Journal of Clinical Oncology</i> , 2015, 33, LBA100-LBA100.	0.8	31
81	Mutational profiling of colorectal cancers with microsatellite instability. <i>Oncotarget</i> , 2015, 6, 42334-42344.	0.8	69
82	Advancements in the Development of HIF-1 $\alpha$ -Activated Protein Switches for Use in Enzyme Prodrug Therapy. <i>PLoS ONE</i> , 2014, 9, e114032.	1.1	9
83	Cytosine Deamination Is a Major Cause of Baseline Noise in Next-Generation Sequencing. <i>Molecular Diagnosis and Therapy</i> , 2014, 18, 587-593.	1.6	129
84	Whole-exome sequencing of pancreatic neoplasms with acinar differentiation. <i>Journal of Pathology</i> , 2014, 232, 428-435.	2.1	151
85	Tumor Cellularity as a Quality Assurance Measure for Accurate Clinical Detection of BRAF Mutations in Melanoma. <i>Molecular Diagnosis and Therapy</i> , 2014, 18, 409-418.	1.6	34
86	Clinical Validation of KRAS, BRAF, and EGFR Mutation Detection Using Next-Generation Sequencing. <i>American Journal of Clinical Pathology</i> , 2014, 141, 856-866.	0.4	128
87	Improved FLT3 Internal Tandem Duplication PCR Assay Predicts Outcome after Allogeneic Transplant for Acute Myeloid Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1989-1995.	2.0	31
88	Haplotype Counting by Next-Generation Sequencing for Ultrasensitive Human DNA Detection. <i>Journal of Molecular Diagnostics</i> , 2014, 16, 495-503.	1.2	17
89	False Positives in Multiplex PCR-Based Next-Generation Sequencing Have Unique Signatures. <i>Journal of Molecular Diagnostics</i> , 2014, 16, 541-549.	1.2	43
90	DNA Mismatch Repair Defects and Microsatellite Instability Status in Periocular Sebaceous Carcinoma. <i>American Journal of Ophthalmology</i> , 2014, 157, 640-647.e2.	1.7	23

#	ARTICLE	IF	CITATIONS
91	Clinicopathological Correlates of Activating GNAS Mutations in Intraductal Papillary Mucinous Neoplasm (IPMN) of the Pancreas. <i>Annals of Surgical Oncology</i> , 2013, 20, 3802-3808.	0.7	158
92	Personalized Chemotherapy Profiling Using Cancer Cell Lines from Selectable Mice. <i>Clinical Cancer Research</i> , 2013, 19, 1139-1146.	3.2	24
93	Tandem Duplication PCR. <i>Diagnostic Molecular Pathology</i> , 2013, 22, 149-155.	2.1	10
94	Mutant <i>GNAS</i> detected in duodenal collections of secretin-stimulated pancreatic juice indicates the presence or emergence of pancreatic cysts. <i>Gut</i> , 2013, 62, 1024-1033.	6.1	160
95	<i>ATM</i> Mutations in Patients with Hereditary Pancreatic Cancer. <i>Cancer Discovery</i> , 2012, 2, 41-46.	7.7	442
96	Loss of expression of the SWI/SNF chromatin remodeling subunit BRG1/SMARCA4 is frequently observed in intraductal papillary mucinous neoplasms of the pancreas. <i>Human Pathology</i> , 2012, 43, 585-591.	1.1	56
97	Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. <i>Nature</i> , 2012, 491, 399-405.	13.7	1,741
98	Ψ-PCR, A Simple Method to Detect Translocations and Insertion/Deletion Mutations. <i>Journal of Molecular Diagnostics</i> , 2011, 13, 85-92.	1.2	17
99	Recurrent <i>GNAS</i> Mutations Define an Unexpected Pathway for Pancreatic Cyst Development. <i>Science Translational Medicine</i> , 2011, 3, 92ra66.	5.8	703
100	Analysis of Hematopoietic Stem Cell Transplant Engraftment. <i>Diagnostic Molecular Pathology</i> , 2011, 20, 194-202.	2.1	6
101	A protein therapeutic modality founded on molecular regulation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 16206-16211.	3.3	41
102	Whole-exome sequencing of neoplastic cysts of the pancreas reveals recurrent mutations in components of ubiquitin-dependent pathways. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 21188-21193.	3.3	585
103	Distant metastasis occurs late during the genetic evolution of pancreatic cancer. <i>Nature</i> , 2010, 467, 1114-1117.	13.7	2,184
104	Verification and Unmasking of Widely Used Human Esophageal Adenocarcinoma Cell Lines. <i>Journal of the National Cancer Institute</i> , 2010, 102, 271-274.	3.0	116
105	Comparison of Sanger Sequencing, Pyrosequencing, and Melting Curve Analysis for the Detection of KRAS Mutations. <i>Journal of Molecular Diagnostics</i> , 2010, 12, 425-432.	1.2	422
106	Exomic Sequencing Identifies <i>PALB2</i> as a Pancreatic Cancer Susceptibility Gene. <i>Science</i> , 2009, 324, 217-217.	6.0	713
107	Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses. <i>Science</i> , 2008, 321, 1801-1806.	6.0	3,755
108	Application of Traditional Clinical Pathology Quality Control Techniques to Molecular Pathology. <i>Journal of Molecular Diagnostics</i> , 2008, 10, 142-146.	1.2	17

#	ARTICLE	IF	CITATIONS
109	Sensitive and quantitative detection of KRAS2 gene mutations in pancreatic duct juice differentiates patients with pancreatic cancer from chronic pancreatitis, potential for early detection. <i>Cancer Biology and Therapy</i> , 2008, 7, 353-360.	1.5	67
110	Genetic and Epigenetic Alterations of Familial Pancreatic Cancers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2008, 17, 3536-3542.	1.1	79
111	Anti-gene padlocks eliminate Escherichia coli based on their genotype. <i>Journal of Antimicrobial Chemotherapy</i> , 2008, 61, 262-272.	1.3	4
112	Familial pancreatic cancer: from genes to improved patient care. <i>Expert Review of Gastroenterology and Hepatology</i> , 2007, 1, 81-88.	1.4	16
113	Evaluation of the Cepheid GeneXpert BCR-ABL Assay. <i>Journal of Molecular Diagnostics</i> , 2007, 9, 220-227.	1.2	44
114	Comparison of the Microsatellite Instability Analysis System and the Bethesda Panel for the Determination of Microsatellite Instability in Colorectal Cancers. <i>Journal of Molecular Diagnostics</i> , 2006, 8, 305-311.	1.2	234
115	LigAmp for sensitive detection of single-nucleotide differences. <i>Nature Methods</i> , 2004, 1, 141-147.	9.0	366
116	Conversion of diploidy to haploidy. <i>Nature</i> , 2000, 403, 723-724.	13.7	248
117	Use of Single Nucleotide Polymorphisms (SNP) and Real-Time Polymerase Chain Reaction for Bone Marrow Engraftment Analysis. <i>Journal of Molecular Diagnostics</i> , 2000, 2, 202-208.	1.2	58
118	Detection of Microsatellite Instability by Fluorescence Multiplex Polymerase Chain Reaction. <i>Journal of Molecular Diagnostics</i> , 2000, 2, 20-28.	1.2	133
119	Leukemia Arising out of Paroxysmal Nocturnal Hemoglobinuria. <i>Leukemia and Lymphoma</i> , 1999, 32, 401-426.	0.6	57
120	Chromosome number and structure both are markedly stable in RER colorectal cancers and are not destabilized by mutation of p53. <i>Oncogene</i> , 1998, 17, 719-725.	2.6	116
121	Mismatch repair defects in human carcinogenesis. <i>Human Molecular Genetics</i> , 1996, 5, 1489-1494.	1.4	217